Blog
RSS FeedPosted by Michael Wonder on 11 Feb 2024
Desperate PHARMAC plea from family selling cans for unfunded myeloma cancer drugs
11 February 2024 - Multiple myeloma, a common blood cancer, is incurable, but can be survived for years with the right ...
Posted by Michael Wonder on 10 Feb 2024
Isatuximab in combination with pomalidomide and dexamethasone for the treatment of patients with relapsed and refractory multiple myeloma
9 February 2024 - NICE is reviewing its guidance on the use of isatuximab for the treatment of patients with ...
Posted by Michael Wonder on 10 Feb 2024
Janssen submits type II extension of indication application to the EMA seeking approval of Rybrevant (amivantamab), in combination with lazertinib, for first-line treatment of patients with EGFR mutated non-small-cell lung cancer
8 February 2024 - The submission is supported by data from the Phase 3 MARIPOSA study, showing statistically significant and clinically ...
Posted by Michael Wonder on 08 Feb 2024
Health Canada approves Brukinsa (zanubrutinib) for the treatment of relapsed or refractory follicular lymphoma
7 February 2024 - Brukinsa is the first and only BTK inhibitor approved for follicular lymphoma in Canada. ...
Posted by Michael Wonder on 07 Feb 2024
Bristol Myers Squibb announces acceptance of US and EU regulatory filings for neo-adjuvant Opdivo (nivolumab) and chemotherapy followed by surgery and adjuvant Opdivo in resectable non-small cell lung cancer
7 February 2024 - Applications based on results from CheckMate-77T, the company’s second positive Phase 3 randomised trial with an immunotherapy-based ...
Posted by Michael Wonder on 07 Feb 2024
Nivolumab with relatlimab for the treatment of patients with unresectable or metastatic melanoma
7 February 2024 - NICE has published final evidence-based recommendations on the use of nivolumab with relatlimab (Opdualag) for the ...
Posted by Michael Wonder on 06 Feb 2024
Arvinas and Pfizer’s vepdegestrant (ARV-471) receives FDA fast track designation for the treatment of patients with ER positive/HER2 negative metastatic breast cancer
6 February 2024 - Vepdegestrant is an investigational PROteolysis Targeting Chimera (PROTAC) protein degrader designed to target and degrade the ...
Posted by Michael Wonder on 05 Feb 2024
Ultimovacs receives FDA fast track designation for UV1 cancer vaccine for the treatment of patients with unresectable mesothelioma
5 February 2024 - The designation was granted by the US FDA based on results from the randomised Phase II clinical ...
Posted by Michael Wonder on 05 Feb 2024
Selinexor in combination with bortezomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma
2 February 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 05 Feb 2024
Cheaper medicines for advanced melanoma and multiple sclerosis
5 February 2024 - From 1 February 2024, Australians with advanced melanoma and relapsing-remitting multiple sclerosis will have access to ...
Posted by Michael Wonder on 03 Feb 2024
Pfizer's Bosulif for leukaemia gains insurance coverage, patients urge inclusion for children, first-line use
3 January 2024 - Pfizer's second generation targeted therapy for chronic myeloid leukaemia, Bosulif (bosutinib), has been newly registered with ...
Posted by Michael Wonder on 02 Feb 2024
Linvoseltamab receives EMA filing acceptance for treatment of relapsed/refractory multiple myeloma
2 February 2024 - Regeneron Pharmaceuticals today announced that the EMA has accepted for review the marketing authorisation application for linvoseltamab ...
Posted by Michael Wonder on 01 Feb 2024
Biosyngen announces FDA fast track designation for BST02 in treatment of liver cancer
1 February 2024 - Biosyngen is proud to announce that its latest groundbreaking product, BST02, has been granted fast track designation ...
Posted by Michael Wonder on 01 Feb 2024
Ivosidenib for the treatment of patients with advanced IDH1 R132 mutation positive cholangiocarcinoma after one or more systemic treatments
31 January 2024 - NICE has published final evidence-based recommendations on the use of ivosidenib (Tibsovo) for the treatment of ...
Posted by Michael Wonder on 01 Feb 2024
Adaptimmune announces US FDA acceptance of biologics license application for afami-cel for the treatment of advanced synovial sarcoma with priority review
31 January 2024 - Adaptimmune Therapeutics today announced that the US FDA has accepted for priority review its biologics license application ...